XML 272 R215.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segment information - Summary of Net Sales by Segment and Geographical Area (Details) - EUR (€) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | € 41,081 | € 37,817 | [1] | € 37,651 | [1] |  |
Biopharma (operating segment) |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 41,081 | 37,817 | [2],[3] | 37,651 | [3],[4],[5] |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |
Business operating income | 11,285 | 11,155 | [2] | 12,764 | [4],[5] |  |
Biopharma (operating segment) | Dupixent [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 13,072 | 10,715 | [3] | 8,292 | [3] |  |
Biopharma (operating segment) | Aubagio [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales |  | 379 |  | 955 | [3] | € 2,029 | [3]
Biopharma (operating segment) | Cerezyme [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales |  |  |  | 686 |  |  |
Biopharma (operating segment) | Fabrazyme [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales |  |  |  | 990 |  |  |
Biopharma (operating segment) | Myozyme Or Lumizyme [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales |  |  |  | 782 |  |  |
Biopharma (operating segment) | Lovenox [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales |  |  |  | 1,122 |  |  |
Biopharma (operating segment) | Industrial Sales [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 523 | 551 | [3] | 608 | [3] |  |
Biopharma (operating segment) | Vaccines [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales |  | 7,477 |  |  |  |  |
Biopharma (operating segment) | Polio Pertussis Hib Vaccines [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 2,741 | 2,766 | [3] | 2,860 | [3] |  |
Biopharma (operating segment) | Influenza Vaccines [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 2,555 | 2,669 | [3] | 2,977 | [3] |  |
Biopharma (operating segment) | RSV Vaccines (Beyfortus) |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 1,686 | 547 | [3] | 0 | [3] |  |
Biopharma (operating segment) | Meningitis, Travel And Endemics Vaccines |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 1,316 | 1,266 | [3] | 1,309 | [3] |  |
Biopharma (operating segment) | Nexviazyme |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 667 | 425 | [3] | 196 | [3] |  |
Biopharma (operating segment) | Sarclisa |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 471 | 381 | [3] | 294 | [3] |  |
Biopharma (operating segment) | ALTUVIIIO |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 682 | 159 | [3] | 0 | [3] |  |
Biopharma (operating segment) | Rezurock |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 470 | 310 | [3] | 207 | [3] |  |
Biopharma (operating segment) | Cablivi |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 249 | 227 | [3] | 211 | [3] |  |
Biopharma (operating segment) | Xenpozyme |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 151 | 91 | [3] | 21 | [3] |  |
Biopharma (operating segment) | Enjaymo |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 105 | 72 | [3] | 22 | [3] |  |
Biopharma (operating segment) | Tzield |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 54 | 25 | [3] | 0 | [3] |  |
Libtayo Segment |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |
Business operating income |  |  |  | 952 |  |  |
Business Operating Income, Net of Tax |  |  |  | 706 |  |  |
Europe |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 9,027 | 8,816 | [6] | 8,490 | [7] |  |
Europe | Biopharma (operating segment) |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 9,027 | 8,816 |  | 8,490 |  |  |
Europe | Biopharma (operating segment) | Dupixent [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 1,618 | 1,224 |  | 940 |  |  |
Europe | Biopharma (operating segment) | Aubagio [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales |  | 152 |  | 437 |  | 511 |
Europe | Biopharma (operating segment) | Industrial Sales [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 520 | 528 |  | 580 |  |  |
Europe | Biopharma (operating segment) | Polio Pertussis Hib Vaccines [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 497 | 477 |  | 479 |  |  |
Europe | Biopharma (operating segment) | Influenza Vaccines [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 640 | 694 |  | 681 |  |  |
Europe | Biopharma (operating segment) | RSV Vaccines (Beyfortus) |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 440 | 140 |  | 0 |  |  |
Europe | Biopharma (operating segment) | Meningitis, Travel And Endemics Vaccines |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 204 | 157 |  | 112 |  |  |
Europe | Biopharma (operating segment) | Nexviazyme |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 201 | 100 |  | 17 |  |  |
Europe | Biopharma (operating segment) | Sarclisa |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 134 | 111 |  | 88 |  |  |
Europe | Biopharma (operating segment) | ALTUVIIIO |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 0 | 0 |  | 0 |  |  |
Europe | Biopharma (operating segment) | Rezurock |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 28 | 5 |  | 1 |  |  |
Europe | Biopharma (operating segment) | Cablivi |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 93 | 98 |  | 94 |  |  |
Europe | Biopharma (operating segment) | Xenpozyme |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 46 | 31 |  | 15 |  |  |
Europe | Biopharma (operating segment) | Enjaymo |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 17 | 6 |  | 0 |  |  |
Europe | Biopharma (operating segment) | Tzield |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 1 | 0 |  | 0 |  |  |
United States |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 19,986 | 17,262 | [6] | 16,986 | [7] |  |
United States | Biopharma (operating segment) |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 19,986 | 17,262 |  | 16,986 |  |  |
United States | Biopharma (operating segment) | Dupixent [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 9,544 | 8,145 |  | 6,346 |  |  |
United States | Biopharma (operating segment) | Aubagio [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales |  | 187 |  | 460 |  | 1,420 |
United States | Biopharma (operating segment) | Fabrazyme [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales |  |  |  | 503 |  |  |
United States | Biopharma (operating segment) | Industrial Sales [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 1 | 4 |  | 17 |  |  |
United States | Biopharma (operating segment) | Polio Pertussis Hib Vaccines [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 679 | 721 |  | 787 |  |  |
United States | Biopharma (operating segment) | Influenza Vaccines [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 1,433 | 1,406 |  | 1,737 |  |  |
United States | Biopharma (operating segment) | RSV Vaccines (Beyfortus) |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 1,068 | 407 |  | 0 |  |  |
United States | Biopharma (operating segment) | Meningitis, Travel And Endemics Vaccines |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 736 | 730 |  | 767 |  |  |
United States | Biopharma (operating segment) | Nexviazyme |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 361 | 272 |  | 158 |  |  |
United States | Biopharma (operating segment) | Sarclisa |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 200 | 165 |  | 127 |  |  |
United States | Biopharma (operating segment) | ALTUVIIIO |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 617 | 155 |  | 0 |  |  |
United States | Biopharma (operating segment) | Rezurock |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 425 | 303 |  | 206 |  |  |
United States | Biopharma (operating segment) | Cablivi |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 136 | 112 |  | 110 |  |  |
United States | Biopharma (operating segment) | Xenpozyme |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 81 | 52 |  | 5 |  |  |
United States | Biopharma (operating segment) | Enjaymo |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 58 | 42 |  | 17 |  |  |
United States | Biopharma (operating segment) | Tzield |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 52 | 25 |  | 0 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 12,068 | 11,739 |  | 12,175 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Dupixent [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 1,910 | 1,346 |  | 1,006 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Aubagio [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales |  | 40 |  | 58 |  | € 98 |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Cerezyme [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales |  |  |  | 268 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Fabrazyme [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales |  |  |  | 246 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Industrial Sales [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 2 | 19 |  | 11 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Polio Pertussis Hib Vaccines [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 1,565 | 1,568 |  | 1,594 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Influenza Vaccines [Member] |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 482 | 569 |  | 559 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | RSV Vaccines (Beyfortus) |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 178 | 0 |  | 0 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Meningitis, Travel And Endemics Vaccines |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 376 | 379 |  | 430 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Nexviazyme |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 105 | 53 |  | 21 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Sarclisa |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 137 | 105 |  | 79 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | ALTUVIIIO |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 65 | 4 |  | 0 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Rezurock |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 17 | 2 |  | 0 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Cablivi |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 20 | 17 |  | 7 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Xenpozyme |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 24 | 8 |  | 1 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Enjaymo |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | 30 | 24 |  | 5 |  |  |
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Tzield |  |  |  |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |  |  |  |
Net sales | € 1 | € 0 |  | € 0 |  |  |
[1] | Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] | Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] | (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[4] | (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[5] | (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€706 million net of tax).
[6] | (a)Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[7] | (a)Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfGeographicalAreasLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue arising from the sale of goods. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business operating income. + References No definition available. + Details
Name: | sny_BusinessOperatingIncome
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Operating Income, Net of Tax + References No definition available. + Details
Name: | sny_BusinessOperatingIncomeNetOfTax
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_DupixentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_AubagioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_CerezymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_FabrazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_MyozymeOrLumizymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_LovenoxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_VaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_InfluenzaVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_RSVVaccinesBeyfortusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_MeningitisTravelAndEndemicsVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_NexviazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_SarclisaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_ALTUVIIIOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_RezurockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_CabliviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_XenpozymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_EnjaymoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_TzieldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_LibtayoSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |